# Raised liver enzymes on targeted anticancer drugs: monitoring, hold and stop rules

Source: https://onco.cc/protocols/raised-liver-enzymes-on-targeted-anticancer-drugs/  
OnCo record `raised-liver-enzymes-on-targeted-anticancer-drugs` (Protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Many cancer tablets and some infusions can irritate the liver, sometimes with no symptoms, so liver blood tests are taken before treatment and at set intervals after. A mild rise is watched, a larger one means a pause and often a lower dose, and a rise with jaundice usually means stopping. Yellow skin or eyes, dark urine or itching need a call to your cancer team straight away.

## Summary

Liver injury from kinase inhibitors, CDK4/6 inhibitors, KRAS and IDH inhibitors and some antibody-drug conjugates can be silent and is then found only on blood tests. Each label sets its own schedule and its own thresholds, and the label of the drug being taken is the rule; the reader's own team's protocol comes first.

Monitoring schedules in the US labels read, after a baseline test: ribociclib every 2 weeks for the first 2 cycles, then at the start of each of the next 4 cycles; abemaciclib every 2 weeks for 2 months, then monthly for 2 months; tucatinib every 2 weeks for 2 months, then every 3 weeks throughout; pazopanib at weeks 3, 5, 7 and 9 and at months 3 and 4; sotorasib every 3 weeks for 3 months, then monthly; adagrasib monthly for 3 months; selpercatinib every 2 weeks for 3 months, then monthly; vorasidenib every 2 weeks for 2 months, then monthly for the first 2 years; ponatinib at least monthly; lapatinib every 4 to 6 weeks; trastuzumab emtansine and trabectedin before each dose. All except the trastuzumab emtansine sentence add 'as clinically indicated'.

When ALT or AST is confirmed above 3 times the upper limit of normal (ULN), the FDA guidance (written for trials) advises close observation at once: repeat tests two or three times a week, a history of other medicines, supplements and alcohol, and exclusion of viral hepatitis A to E, autoimmune and alcoholic hepatitis, fatty liver disease, ischaemia and biliary disease. AASLD 2023 recommends viral serology and liver imaging for all suspected cases. In its section on checkpoint inhibitors it adds that recent studies suggest drug injury accounts for only 30% of demonstrable liver injury in advanced cancer, the rest being metastases, sepsis and other causes.

Hold thresholds differ by label. Pazopanib continues through an isolated ALT of 3 to 8 times ULN with weekly tests and is withheld above 8 times. Abemaciclib is withheld for persistent or recurrent grade 2 or for grade 3 (more than 5 to 20 times ULN). Ribociclib is interrupted from grade 2 if the baseline was below grade 2. Sotorasib is withheld above 5 times ULN, or above 3 and up to 5 times with symptoms. Vorasidenib is withheld from grade 2. Grade 4 (more than 20 times ULN) ends treatment in the ribociclib, abemaciclib, tucatinib and vorasidenib labels.

ALT or AST above 3 times ULN with bilirubin above 2 times ULN and no cholestasis or other cause (a Hy's law case) is the stop signal: the FDA guidance puts the risk of death or transplant at roughly one tenth of such cases. Ribociclib, abemaciclib, tucatinib and pazopanib are stopped permanently; sotorasib and adagrasib are stopped if no other cause is found, and the trastuzumab emtansine dose table says the same (its warning section gives the stop without that condition); the vorasidenib label alone allows a reduced dose after recovery from a first occurrence.

Corticosteroids are not routine: EASL 2019 says routine use 'may not be substantiated' (Grade C) and AASLD 2023 says they may be of benefit in selected patients, including those with severe hypersensitivity features or autoimmune features on biopsy. The sotorasib label is an exception: it says to consider systemic corticosteroids, and records hepatotoxicity in 40% of patients who had immunotherapy in the 3 months before starting against 17% of those never given it. On restarting, EASL considers controlled rechallenge justified in oncology (Grade B; 38% of 103 rechallenged pazopanib patients had a recurrence, none severe), AASLD says rechallenge should generally be avoided unless the benefit is high, and the tucatinib label warns of severe and fatal injury after rechallenge.

Four drugs read on 18 November 2026. Gilteritinib has no liver warning in either label: blood chemistries are assessed at least weekly for the first month, every other week for the second and then monthly in the US label, and on day 15 and then monthly in the EU SmPC; a grade 3 or higher toxicity considered related to treatment interrupts the drug until grade 1, resuming at 80 mg (US) or at 80 mg or 120 mg (EU). Olutasidenib (US label only): liver tests at least weekly for 2 months, every other week in the third month, once in the fourth and then every other month; grade 3 withholds with tests twice a week and a restart at 150 mg once daily; grade 4, or a Hy's law pattern with alkaline phosphatase below 2 times ULN and no clear other explanation, is a permanent stop. Enasidenib (US label only): its label says it may interfere with bilirubin metabolism through inhibition of UGT1A1; 89% of the patients whose bilirubin reached 2 times ULN had no accompanying transaminase rise, and the rule is a dose reduction to 50 mg daily, not a hold, when bilirubin stays above 3 times ULN for 2 weeks or more without raised transaminases or other hepatic disorders. Loncastuximab tesirine: the US label asks for liver tests at baseline and throughout treatment, withholds for a grade 3 or higher ALT or AST rise or suspected drug-induced liver injury and discontinues if that injury is confirmed; the EU SmPC has no liver warning and no liver row. A raised GGT on its own (57% in the US label, 21% at grade 3 or 4) falls under both labels' general row, which withholds at grade 3 or higher.

## Fields

- Kind: Protocol
- Last checked: 2026-11-18
- Also known as: drug-induced liver injury on cancer drugs; DILI on kinase inhibitors; raised ALT on targeted therapy; raised AST on targeted therapy; transaminitis on TKIs; hepatotoxicity monitoring; liver function tests on CDK4/6 inhibitors; Hy's law

## Connected records

- protocols: [Hepatic dose adjustment of anticancer drugs in reduced liver function](https://onco.cc/protocols/hepatic-dose-adjustment-of-anticancer-drugs/), [Immune-mediated hepatitis from checkpoint inhibitors, by grade](https://onco.cc/protocols/irae-hepatitis/), [Liver toxicity and veno-occlusive disease on inotuzumab ozogamicin and gemtuzumab ozogamicin: risk reduction, monitoring, hold and stop rules](https://onco.cc/protocols/veno-occlusive-disease-on-inotuzumab-and-gemtuzumab-ozogamicin/), [Pancreatitis and raised pancreatic enzymes on asciminib, ponatinib, nilotinib and bosutinib: monitoring, hold and stop rules](https://onco.cc/protocols/pancreatitis-and-raised-pancreatic-enzymes-on-targeted-drugs/), [Veno-occlusive disease of the liver (sinusoidal obstruction syndrome) after stem cell transplant: prevention, monitoring, diagnosis and defibrotide](https://onco.cc/protocols/hepatic-veno-occlusive-disease-after-transplant/)
- drugs: [Abemaciclib](https://onco.cc/drugs/abemaciclib/), [Adagrasib](https://onco.cc/drugs/adagrasib/), [Enasidenib](https://onco.cc/drugs/enasidenib/), [Gilteritinib](https://onco.cc/drugs/gilteritinib/), [Lapatinib](https://onco.cc/drugs/lapatinib/), [Loncastuximab tesirine](https://onco.cc/drugs/zynlonta/), [Olutasidenib](https://onco.cc/drugs/olutasidenib/), [Pazopanib](https://onco.cc/drugs/pazopanib/), [Ponatinib](https://onco.cc/drugs/ponatinib/), [Ribociclib](https://onco.cc/drugs/ribociclib/), [Selpercatinib](https://onco.cc/drugs/selpercatinib/), [Sotorasib](https://onco.cc/drugs/sotorasib/), [Trabectedin](https://onco.cc/drugs/trabectedin/), [Trastuzumab emtansine](https://onco.cc/drugs/trastuzumab-emtansine/), [Tucatinib](https://onco.cc/drugs/tucatinib/), [Vorasidenib](https://onco.cc/drugs/vorasidenib/)
- terms: [CTCAE toxicity grading (grade 3-4 adverse events)](https://onco.cc/terms/ctcae-grading/), [Hepatotoxicity (liver enzyme elevation)](https://onco.cc/terms/hepatotoxicity/)

---
JSON: https://onco.cc/api/v1/entities/raised-liver-enzymes-on-targeted-anticancer-drugs.json